{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:15:24Z","timestamp":1783728924246,"version":"3.55.0"},"reference-count":76,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review focuses on significant advances in the field of pediatric hemostasis and thrombosis, with a focus on published studies within the past decade. The evaluation and management of patients with excessive bleeding remain cornerstones of consultative hematology. We will describe the development of validated bleeding assessment tools relevant to pediatric practice, laboratory advances in the evaluation of von Willebrand disease, and a shift in clinical practice regarding the interpretation of normal coagulation studies in patients with significant bleeding phenotypes. There have also been critical advances in the management of hemostatic disorders. This review highlights new treatment paradigms in hemophilia and the rise of multidisciplinary medical homes for women living with bleeding disorders. Given the continued increase in the incidence of thrombosis, particularly in the hospital setting, a full call to arms against pediatric venous thromboembolism is now essential. We will describe recently completed clinical trials of direct oral anticoagulants in children and adolescents and ongoing work to elucidate the appropriate duration of therapy for children with provoked thrombosis. Recent work regarding the prevention of pediatric venous thromboembolism is highlighted, including studies of thromboprophylaxis and the development of risk prediction models for hospital-acquired thrombosis. Finally, we review advances in our understanding of thrombotic sequelae and the need for continued refinement of our evaluation tools. Despite the significant advances in pediatric hemostasis and thrombosis over the past decade, many unanswered questions remain for the next generation of investigators.<\/jats:p>","DOI":"10.1182\/blood.2020006477","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T20:04:31Z","timestamp":1635797071000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Hemostatic and thrombotic disorders in the pediatric patient"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-9746","authenticated-orcid":false,"given":"Sarah H.","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology and"},{"name":"2Department of Pediatrics, The Ohio State University, Columbus, OH;"},{"name":"3Nationwide Children\u2019s Hospital, The Ohio State University College of Medicine, Columbus, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3283-0415","authenticated-orcid":false,"given":"Ayesha","family":"Zia","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology\/Oncology and"},{"name":"4University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2022081115222655200_B1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1538-7836.2009.03499.x","article-title":"Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire","volume":"7","author":"Bowman","year":"2009","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022081115222655200_B2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1538-7836.2010.03796.x","article-title":"Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire","volume":"8","author":"Biss","year":"2010","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022081115222655200_B3","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1111\/hae.12747","article-title":"Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease","volume":"21","author":"Deforest","year":"2015","journal-title":"Haemophilia."},{"issue":"10","key":"2022081115222655200_B4","doi-asserted-by":"crossref","first-page":"e26588","DOI":"10.1002\/pbc.26588","article-title":"Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease","volume":"64","author":"Casey","year":"2017","journal-title":"Pediatr Blood Cancer."},{"issue":"6","key":"2022081115222655200_B5","doi-asserted-by":"crossref","first-page":"e27709","DOI":"10.1002\/pbc.27709","article-title":"Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12\u00a0years","volume":"66","author":"Bui","year":"2019","journal-title":"Pediatr Blood Cancer."},{"issue":"10","key":"2022081115222655200_B6","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1111\/jth.14997","article-title":"Prospective evaluation of ISTH-BAT as a predictor of bleeding disorder in adolescents presenting with heavy menstrual bleeding in a multidisciplinary hematology clinic","volume":"18","author":"Jain","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"22","key":"2022081115222655200_B7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2017-05-782029","article-title":"Advances in the diagnosis and treatment of Von Willebrand disease","volume":"130","author":"Sharma","year":"2017","journal-title":"Blood."},{"issue":"8","key":"2022081115222655200_B8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"3","key":"2022081115222655200_B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ijlh.12218","article-title":"Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin","volume":"36","author":"Graf","year":"2014","journal-title":"Int J Lab Hematol."},{"issue":"14","key":"2022081115222655200_B10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood."},{"issue":"5","key":"2022081115222655200_B11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MOH.0000000000000524","article-title":"The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease","volume":"26","author":"Flood","year":"2019","journal-title":"Curr Opin Hematol."},{"issue":"9","key":"2022081115222655200_B12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.25869","article-title":"Laboratory misdiagnosis of von Willebrand disease in post-menarchal females: a multi-center study","volume":"95","author":"Jaffray","year":"2020","journal-title":"Am J Hematol."},{"issue":"11","key":"2022081115222655200_B13","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/jth.14591","article-title":"Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients","volume":"17","author":"Doshi","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022081115222655200_B14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1365-2516.2010.02210.x","article-title":"How many carriers are there?","volume":"16","author":"Kasper","year":"2010","journal-title":"Haemophilia."},{"key":"2022081115222655200_B15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hae.14094","article-title":"Women and girls with haemophilia: lessons learned","volume":"27","author":"D\u2019Oiron","year":"2021","journal-title":"Haemophilia."},{"issue":"6","key":"2022081115222655200_B16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/hae.13089","article-title":"Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study","volume":"22","author":"James","year":"2016","journal-title":"Haemophilia."},{"issue":"1","key":"2022081115222655200_B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/hae.13891","article-title":"Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia?","volume":"26","author":"Raso","year":"2020","journal-title":"Haemophilia."},{"issue":"2","key":"2022081115222655200_B18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.13423","article-title":"A cross-sectional study of bleeding phenotype in haemophilia A carriers","volume":"170","author":"Paroskie","year":"2015","journal-title":"Br J Haematol."},{"issue":"1","key":"2022081115222655200_B19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-09-3879","article-title":"Bleeding in carriers of hemophilia","volume":"108","author":"Plug","year":"2006","journal-title":"Blood."},{"issue":"8","key":"2022081115222655200_B20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ajh.23754","article-title":"Females with FVIII and FIX deficiency have reduced joint range of motion","volume":"89","author":"Sidonio","year":"2014","journal-title":"Am J Hematol."},{"key":"2022081115222655200_B21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.13506","article-title":"Genotypes, phenotypes and whole genome sequence: approaches from the My Life Our Future haemophilia project","volume":"24","author":"Konkle","year":"2018","journal-title":"Haemophilia."},{"issue":"4","key":"2022081115222655200_B22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/hae.13800","article-title":"An update on the new classification of Ehlers-Danlos syndrome and review of the causes of bleeding in this population","volume":"25","author":"Jesudas","year":"2019","journal-title":"Haemophilia."},{"issue":"1","key":"2022081115222655200_B23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajmg.c.31552","article-title":"The 2017 international classification of the Ehlers-Danlos syndromes","volume":"175","author":"Malfait","year":"2017","journal-title":"Am J Med Genet C Semin Med Genet."},{"issue":"6","key":"2022081115222655200_B24","doi-asserted-by":"crossref","first-page":"e27675","DOI":"10.1002\/pbc.27675","article-title":"Characterizing adolescents with heavy menstrual bleeding and generalized joint hypermobility","volume":"66","author":"Kendel","year":"2019","journal-title":"Pediatr Blood Cancer."},{"issue":"12","key":"2022081115222655200_B25","doi-asserted-by":"crossref","first-page":"e27370","DOI":"10.1002\/pbc.27370","article-title":"Clinical features of children, adolescents, and adults with coexisting hypermobility syndromes and von Willebrand disease","volume":"65","author":"Hall","year":"2018","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"2022081115222655200_B26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/hae.13422","article-title":"High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB)","volume":"24","author":"Gebhart","year":"2018","journal-title":"Haemophilia."},{"issue":"9","key":"2022081115222655200_B27","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jth.14529","article-title":"Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause","volume":"17","author":"Hofer","year":"2019","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022081115222655200_B28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.transci.2019.08.010","article-title":"The evolution of recombinant factor replacement for hemophilia","volume":"58","author":"Sankar","year":"2019","journal-title":"Transfus Apheresis Sci."},{"issue":"4","key":"2022081115222655200_B29","doi-asserted-by":"crossref","first-page":"E39","DOI":"10.3390\/jcm6040039","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J Clin Med."},{"key":"2022081115222655200_B30","article-title":"Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A [abstract]","author":"K\u00f6nigs","year":"2020"},{"issue":"24","key":"2022081115222655200_B31","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood."},{"issue":"16","key":"2022081115222655200_B32","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with\/without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood."},{"issue":"9","key":"2022081115222655200_B33","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation","volume":"18","author":"Harkins Druzgal","year":"2020","journal-title":"J Thromb Haemost."},{"key":"2022081115222655200_B34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000 Res."},{"issue":"2","key":"2022081115222655200_B35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/hae.12836","article-title":"Developing a multidisciplinary Young Women\u2019s Blood Disorders Program: a single-centre approach with guidance for other centres","volume":"22","author":"Zia","year":"2016","journal-title":"Haemophilia."},{"key":"2022081115222655200_B36","article-title":"Welcome to the Foundation\u2019s Learning Action Networks (LANs)!","author":"The Women and Girls Bleeding Disorder Learning Action Network","year":"2021"},{"issue":"13","key":"2022081115222655200_B37","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1182\/bloodadvances.2020002081","article-title":"The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding","volume":"4","author":"Srivaths","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2022081115222655200_B38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/bloodadvances.2021005118","article-title":"Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations","volume":"6","author":"Sadler","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"2022081115222655200_B39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2005.05.020","article-title":"Difficulties in performing clinical trials of antithrombotic therapy in neonates and children","volume":"118","author":"Massicotte","year":"2006","journal-title":"Thromb Res."},{"issue":"7","key":"2022081115222655200_B40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004340","article-title":"The phase 3 pediatric anticoagulant era","volume":"135","author":"Goldenberg","year":"2020","journal-title":"Blood."},{"issue":"22","key":"2022081115222655200_B41","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","article-title":"American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism","volume":"2","author":"Monagle","year":"2018","journal-title":"Blood Adv."},{"key":"2022081115222655200_B42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/asheducation.V2012.1.439.3798661","article-title":"Updates in thrombosis in pediatrics: where are we after 20 years?","volume":"2012","author":"Chan","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"1","key":"2022081115222655200_B43","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol."},{"issue":"7","key":"2022081115222655200_B44","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"26","key":"2022081115222655200_B45","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"2022081115222655200_B46","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomized, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol."},{"issue":"5","key":"2022081115222655200_B47","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/jth.15277","article-title":"Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism","volume":"19","author":"R\u00f6shammar","year":"2021","journal-title":"J Thromb Haemost."},{"key":"2022081115222655200_B48","doi-asserted-by":"crossref","first-page":"e737S","DOI":"10.1378\/chest.11-2308","article-title":"Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Monagle","year":"2012","journal-title":"Chest."},{"issue":"2","key":"2022081115222655200_B49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.23182","article-title":"Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT Randomized Clinical Trial","volume":"327","author":"Goldenberg","year":"2022","journal-title":"JAMA."},{"issue":"9","key":"2022081115222655200_B50","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jth.13038","article-title":"Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the\u00a0Kids-DOTT trial): pilot\/feasibility phase findings","volume":"13","author":"Goldenberg","year":"2015","journal-title":"J Thromb Haemost."},{"issue":"19","key":"2022081115222655200_B51","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1182\/bloodadvances.2020002637","article-title":"Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)","volume":"4","author":"Thom","year":"2020","journal-title":"Blood Adv."},{"key":"2022081115222655200_B52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2020.02.013","article-title":"Do asymptomatic clots in children matter?","volume":"189","author":"Jones","year":"2020","journal-title":"Thromb Res."},{"issue":"8","key":"2022081115222655200_B53","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2018-05-849737","article-title":"The natural history of asymptomatic central venous catheter-related thrombosis in critically ill children","volume":"133","author":"Jones","year":"2019","journal-title":"Blood."},{"issue":"5","key":"2022081115222655200_B54","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/jth.14739","article-title":"Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: a systematic review","volume":"18","author":"Sharathkumar","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"7","key":"2022081115222655200_B55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0031-1297162","article-title":"The coagulation system in children: developmental and pathophysiological considerations","volume":"37","author":"Ignjatovic","year":"2011","journal-title":"Semin Thromb Hemost."},{"key":"2022081115222655200_B56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/asheducation.V2015.1.111.3917444","article-title":"Anticoagulants in children and adolescents","volume":"2015","author":"Young","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"7","key":"2022081115222655200_B57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brand\u00e3o","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2022081115222655200_B58","first-page":"235","article-title":"Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study","volume":"90","author":"Mitchell","year":"2003","journal-title":"Thromb Haemost."},{"issue":"4","key":"2022081115222655200_B59","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT \u2013 a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica."},{"issue":"4","key":"2022081115222655200_B60","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2018.209528","article-title":"THROMBOTECT takes the lead","volume":"104","author":"Male","year":"2019","journal-title":"Haematologica."},{"issue":"4","key":"2022081115222655200_B61","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1542\/peds.2009-0768","article-title":"Dramatic increase in venous thromboembolism in children\u2019s hospitals in the United States from 2001 to 2007","volume":"124","author":"Raffini","year":"2009","journal-title":"Pediatrics."},{"issue":"12","key":"2022081115222655200_B62","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/bloodadvances.2017013292","article-title":"Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014","volume":"2","author":"Carpenter","year":"2018","journal-title":"Blood Adv."},{"key":"2022081115222655200_B63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.09.016","article-title":"Development of a risk model for pediatric hospital-acquired thrombosis: a report from the Children\u2019s Hospital-Acquired Thrombosis Consortium","volume":"228","author":"Jaffray","year":"2021","journal-title":"J Pediatr."},{"issue":"11","key":"2022081115222655200_B64","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3324\/haematol.2010.026989","article-title":"Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors","volume":"95","author":"Goldenberg","year":"2010","journal-title":"Haematologica."},{"issue":"3","key":"2022081115222655200_B65","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pbc.24840","article-title":"Health-related quality of life in children and young adults with post-thrombotic syndrome: results from a cross-sectional study","volume":"61","author":"Kumar","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"3-4","key":"2022081115222655200_B66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000090937","article-title":"Postthrombotic syndrome in children","volume":"115","author":"Manco-Johnson","year":"2006","journal-title":"Acta Haematol."},{"issue":"10","key":"2022081115222655200_B67","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/jth.14984","article-title":"Predictors of postthrombotic syndrome in pediatric thrombosis: a systematic review and meta-analysis of the literature","volume":"18","author":"Engel","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"8","key":"2022081115222655200_B68","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/MPH.0000000000000399","article-title":"Comparison of 3 postthrombotic syndrome assessment scales demonstrates significant variability in children and adolescents with deep vein thrombosis","volume":"37","author":"Raffini","year":"2015","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"2022081115222655200_B69","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1538-7836.2011.04594.x","article-title":"Definition of post-thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations","volume":"10","author":"Goldenberg","year":"2012","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022081115222655200_B70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2006-12-061234","article-title":"A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children","volume":"110","author":"Goldenberg","year":"2007","journal-title":"Blood."},{"issue":"10","key":"2022081115222655200_B71","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/j.1538-7836.2012.04885.x","article-title":"Standardization of post-thrombotic syndrome definition and outcome assessment following upper venous system thrombosis in pediatric practice","volume":"10","author":"Revel-Vilk","year":"2012","journal-title":"J Thromb Haemost."},{"issue":"4","key":"2022081115222655200_B72","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/rth2.12251","article-title":"Post-thrombotic syndrome in children: measurement properties of CAPTSure, a new diagnostic tool","volume":"3","author":"Avila","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"issue":"12","key":"2022081115222655200_B73","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/jth.13530","article-title":"Development of CAPTSureTM \u2013 a new index for the assessment of pediatric postthrombotic syndrome","volume":"14","author":"Avila","year":"2016","journal-title":"J Thromb Haemost."},{"issue":"2","key":"2022081115222655200_B74","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/rth2.12099","article-title":"Characteristics of pain, other symptoms and function in pediatric post-thrombotic syndrome","volume":"2","author":"Avila","year":"2018","journal-title":"Res Pract Thromb Haemost."},{"issue":"2","key":"2022081115222655200_B75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor Xia as a therapeutic approach for safe thromboprotection","volume":"19","author":"Demoulin","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"10","key":"2022081115222655200_B76","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17474086.2016.1230012","article-title":"Novel perspectives on diagnosis and clinical significance of the post-thrombotic syndrome in children","volume":"9","author":"Jones","year":"2016","journal-title":"Expert Rev Hematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/6\/533\/1912864\/bloodbld2020006477c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/6\/533\/1912864\/bloodbld2020006477c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T02:47:03Z","timestamp":1699757223000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/6\/533\/477733\/Hemostatic-and-thrombotic-disorders-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020006477","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}